Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BCR | P11274 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | TEK | Q02763 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 10/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6128693 | 0.83 | EGFR (0.39) | ABL1BCRKDRAKT3MKNK1 | |
| SCHEMBL2176307 | 0.81 | KDR (0.41) | ABL1BCRKDRHDAC3NCOR1 | |
| SCHEMBL2178871 | 0.81 | MEN1 (0.37) | ABL1BCRPRKCAPRKACBHDAC3 | |
| SCHEMBL6128772 | 0.80 | NPC1 (0.44) | HDAC3NCOR1HDAC2GSK3B | |
| SCHEMBL2178535 | 0.80 | HDAC3 (0.38) | AURKAAURKBHDAC3NCOR1HDAC2 | |
| SCHEMBL2181038 | 0.80 | ABL1 (0.38) | ABL1BCRAURKALCKKDR | |
| SCHEMBL2179091 | 0.79 | HDAC3 (0.39) | AURKAAURKBHDAC3NCOR1HDAC2 | |
| SCHEMBL2178873 | 0.79 | MEN1 (0.37) | ABL1BCRAURKAHDAC3NCOR1 | |
| SCHEMBL2180455 | 0.79 | HDAC3 (0.36) | AURKALCKKDRTEKAURKB | |
| SCHEMBL2178148 | 0.79 | HSD17B1 (0.46) | HDAC3NCOR1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | ABL1 128/4885BCR 694/4885AURKA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.